DNA Ginkgo Bioworks Holdings, Inc. Class A Common Stock

NYSE · Life Sciences Tools & Services · Ver en SEC EDGAR ↗
$9,12
Precio · Jun 23, 2026
Fundamentales a fecha de May 7, 2026

DNA Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

Precio
$9.12
Capitalización Bursátil
$484M
P/E (TTM)
-1.5
BPA (TTM)
$-5.64
Ingresos (TTM)
$170M
Rendimiento div.
ROE
-55.8%
Deuda/Capital
Rango 52S
$5 – $18

DNA Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

Ingresos y Beneficio Neto $170M
7-point trend, +214.0%
2019-12-31 2025-12-31
BPA $-5.64
7-point trend, -5540.0%
2019-12-31 2025-12-31
Flujo de caja libre $-179M
4-point trend, +41.3%
2022-12-31 2025-12-31
Márgenes -183.8%

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica
Tendencia a 5 años
DNA
Mediana de Pares
P/E (TTM)
5-point trend, +99.4%
-1.5
18.0
P/S (TTM) (P/V (TTM))
4-point trend, -98.9%
2.8
3.3
P/B (P/C)
4-point trend, -98.7%
1.0
1.6
Price / FCF (Precio / FCF)
4-point trend, +99.4%
-2.7

Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC

Métrica
Tendencia a 5 años
DNA
Mediana de Pares
Operating Margin (Margen Operativo)
4-point trend, +59.9%
-185.3%
Net Profit Margin (Margen de Beneficio Neto)
4-point trend, +58.3%
-183.8%
-21.2%
ROA
4-point trend, +72.6%
-25.1%
-8.2%
ROE
4-point trend, +57.9%
-55.8%
-10.6%
ROIC
4-point trend, +51.1%
-61.8%

Salud financiera Deuda, liquidez, solvencia — solidez del balance general

Métrica
Tendencia a 5 años
DNA
Mediana de Pares
Current Ratio (Ratio corriente)
4-point trend, -41.4%
4.9
4.9
Quick Ratio (Ratio Rápido)
4-point trend, -42.4%
4.7

Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años

Métrica
Tendencia a 5 años
DNA
Mediana de Pares
Revenue YoY (Ingresos interanuales)
5-point trend, -45.8%
-25.1%
Revenue CAGR 3Y (Ingresos CAGR 3A)
5-point trend, -45.8%
-29.1%
Revenue CAGR 5Y (Ingresos CAGR 5A)
5-point trend, -45.8%
17.3%

Métricas por acción BPA, valor contable por acción, flujo de caja por acción, dividendo por acción

Métrica
Tendencia a 5 años
DNA
Mediana de Pares
EPS (Diluted) (BPA (Diluido))
5-point trend, -305.8%
$-5.64

Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar

Métrica
Tendencia a 5 años
DNA
Mediana de Pares

DNA Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

VENTA 10 analistas
  • Compra fuerte 0 0,0%
  • Compra 1 10,0%
  • Mantener 2 20,0%
  • Venta 5 50,0%
  • Venta fuerte 2 20,0%

Precio objetivo a 12 meses

2 analistas · 2026-06-20
Objetivo mediano $8.50 -6,8%
Objetivo medio $8.50 -6,8%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

Sorpresa Media
0.03%
Período EPS Actual EPS est. Sorpresa
31 de marzo de 2026 $-1.39 $-1.09 -0.30%
31 de diciembre de 2025 $-1.41 $-1.47 0.06%
30 de septiembre de 2025 $-1.45 $-1.25 -0.20%
30 de junio de 2025 $-1.10 $-1.58 0.48%
31 de marzo de 2025 $-1.68 $-1.79 0.11%

Comparación con pares Métricas clave frente a competidores del sector

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
DNA $484M -1.5 -25.1% -183.8% -55.8%
MRVI -3.6 -28.3% -70.4% -48.6% 18.3%
BLFS -241.8 28.9%
PSNL $816M -8.7 -17.7% -116.7% -36.0%
AZTA $1.32B -23.5 3.5% -9.4% -3.3% 45.5%
CYRX $479M 6.9 12.4% 44.4% 15.3% 47.1%
MLAB $489M 73.1 3.4% 2.7% 3.7% 63.5%
CTKB $649M 505.0 0.52% -33.0% -18.5% 51.8%
PACB $565M -1.0 3.9% -341.5% -1634.9% 28.6%
OABI
LAB $495M -6.4 -6.2% -87.8% -17.6% 49.9%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

Estado de resultados 15
Datos anuales de Estado de resultados para DNA
Métrica Tendencia 2025202420232022202120202019
Revenue 7-point trend, +214.0% $170M $227M $251M $478M $314M $77M $54M
R&D Expense 7-point trend, +153.1% $244M $424M $581M $1.05B $1.15B $160M $96M
SG&A Expense 7-point trend, +521.7% $183M $246M $385M $1.43B $863M $38M $29M
Operating Expenses 7-point trend, +285.9% $485M $787M $1.12B $2.69B $2.14B $214M $126M
Operating Income 7-point trend, -340.3% $-315M $-560M $-864M $-2.21B $-1.83B $-137M $-72M
Interest Expense 5-point trend, -96.2% · · $93.0K $106.0K $2M $2M $2M
Other Non-op 6-point trend, -86.2% $2M $12M $-29M $88M $-10M $12M ·
Pretax Income 7-point trend, -161.7% $-314M $-548M $-893M $-2.12B $-1.84B $-125M $-120M
Income Tax 7-point trend, -3904.5% $-837.0K $-479.0K $-71.0K $-15M $-1M $2M $22.0K
Net Income 7-point trend, -162.1% $-313M $-547M $-893M $-2.10B $-1.83B $-127M $-119M
EPS (Basic) 7-point trend, -5540.0% $-5.64 $-10.54 $-18.37 $-50.15 $-1.35 $-0.10 $-0.10
EPS (Diluted) 7-point trend, -5540.0% $-5.64 $-10.54 $-18.37 $-50.20 $-1.39 $-0.10 $-0.10
Shares (Basic) 7-point trend, -95.2% 55,457,676 51,894,639 48,610,507 41,976,537 1,359,849,000 1,274,766,915 1,149,000,417
Shares (Diluted) 7-point trend, -95.2% 55,457,676 51,894,639 48,610,507 41,995,972 1,360,373,000 1,274,766,915 1,149,000,417
EBITDA 4-point trend, +85.7% $-315M $-560M $-864M $-2.21B · · ·
Balance general 28
Datos anuales de Balance general para DNA
Métrica Tendencia 2025202420232022202120202019
Cash & Equivalents 7-point trend, -66.2% $167M $562M $944M $1.32B $1.55B $381M $495M
Short-term Investments 2-point trend, +255418000.00 $255M $0 · · · · ·
Receivables 6-point trend, +43.9% $24M $22M $17M $81M $132M $17M ·
Inventory 4-point trend, -98.3% · · $46.0K $4M $3M $3M ·
Prepaid Expense 6-point trend, +18.3% $25M $19M $40M $52M $34M $21M ·
Other Current Assets 4-point trend, -46.8% · · $362.0K $487.0K $698.0K $680.0K ·
Current Assets 6-point trend, +10.6% $472M $603M $1.00B $1.45B $1.72B $427M ·
PP&E (Net) 6-point trend, +37.8% $167M $204M $188M $315M $146M $121M ·
PP&E (Gross) 6-point trend, +128.9% $355M $365M $309M $408M $207M $155M ·
Accum. Depreciation 6-point trend, +456.3% $188M $161M $121M $93M $61M $34M ·
Goodwill 6-point trend, -100.0% · $0 $49M $60M $21M $2M $2M
Intangibles 6-point trend, +1523.6% $53M $73M $83M $111M $22M $3M ·
Other Non-current Assets 6-point trend, +741.8% $47M $55M $58M $89M $44M $6M ·
Total Assets 6-point trend, +65.8% $1.12B $1.38B $1.67B $2.54B $2.07B $675M ·
Accounts Payable 6-point trend, -23.9% $11M $14M $9M $10M $8M $14M ·
Accrued Liabilities 3-point trend, +276.0% · · · $115M $93M $31M ·
Short-term Debt · · · · · $300.0K ·
Current Liabilities 6-point trend, +31.1% $96M $107M $164M $173M $135M $73M ·
Capital Leases 5-point trend, +417078000.00 $417M $439M $222M $413M $0 · ·
Other Non-current Liabilities 6-point trend, +654.5% $23M $17M $24M $31M $36M $3M ·
Total Liabilities 6-point trend, +198.0% $611M $661M $568M $803M $504M $205M ·
Common Stock 6-point trend, -95.3% $6.0K $5.0K $5.0K $190.0K $161.0K $129.0K ·
Paid-in Capital 6-point trend, +616.5% $6.66B $6.56B $6.39B $6.14B $3.80B $929M ·
Retained Earnings 6-point trend, -1214.5% $-6.15B $-5.84B $-5.29B $-4.40B $-2.30B $-468M ·
AOCI 6-point trend, +1851000.00 $2M $-2M $1M $-3M $-2M $0 ·
Stockholders' Equity 6-point trend, +8.2% $509M $716M $1.10B $1.74B $1.57B $470M ·
Liabilities + Equity 6-point trend, +65.8% $1.12B $1.38B $1.67B $2.54B $2.07B $675M ·
Shares Outstanding 6-point trend, -95.5% 58,207,298 54,365,785 50,032,873 47,299,399 40,284,804 1,288,596,000 ·
Flujo de Efectivo 16
Datos anuales de Flujo de Efectivo para DNA
Métrica Tendencia 2025202420232022202120202019
D&A 7-point trend, +448.5% $59M $63M $71M $43M $29M $14M $11M
Stock-based Comp 7-point trend, +10476.7% $82M $112M $230M $1.93B $1.61B $476.0K $771.0K
Deferred Tax 6-point trend, -1364000.00 $-1M $-936.0K $-801.0K $-15M $0 $0 ·
Amort. of Intangibles 7-point trend, +3640.0% $19M $18M $16M $6M $1M $500.0K $500.0K
Restructuring 2-point trend, -41.1% $11M $19M · · · · ·
Operating Cash Flow 7-point trend, -283.0% $-171M $-320M $-296M $-252M $-254M $-136M $-45M
CapEx 7-point trend, -65.5% $8M $63M $41M $52M $57M $58M $22M
Investing Cash Flow 7-point trend, -222.1% $-240M $-62M $-81M $-67M $-73M $-67M $-75M
Stock Issued 3-point trend, +19469000.00 $19M $0 $0 · · · ·
Stock Repurchased · · · · · · $408.0K
Net Stock Activity $19M · · · · · ·
Financing Cash Flow 7-point trend, -95.7% $18M $-2M $-3M $95M $1.53B $90M $410M
Net Change in Cash 7-point trend, -235.1% $-393M $-384M $-380M $-223M $1.21B $-113M $291M
Taxes Paid 6-point trend, +192000.00 $192.0K $0 $23.0K $981.0K $9M $0 ·
Free Cash Flow 4-point trend, +41.3% $-179M $-382M $-336M $-304M · · ·
Levered FCF 2-point trend, -10.4% · · $-336M $-305M · · ·
Rentabilidad 7
Datos anuales de Rentabilidad para DNA
Métrica Tendencia 2025202420232022202120202019
Operating Margin 4-point trend, +59.9% -185.3% -246.5% -343.8% -462.4% · · ·
Net Margin 4-point trend, +58.3% -183.8% -240.9% -355.1% -440.6% · · ·
Pretax Margin 4-point trend, +58.5% -184.3% -241.2% -355.1% -444.1% · · ·
EBITDA Margin 4-point trend, +59.9% -185.3% -246.5% -343.8% -462.4% · · ·
ROA 4-point trend, +72.6% -25.1% -36.0% -42.5% -91.3% · · ·
ROE 4-point trend, +57.9% -55.8% -72.3% -76.0% -132.4% · · ·
ROIC 4-point trend, +51.1% -61.8% -78.1% -78.8% -126.3% · · ·
Liquidez y Solvencia 3
Datos anuales de Liquidez y Solvencia para DNA
Métrica Tendencia 2025202420232022202120202019
Current Ratio 4-point trend, -41.4% 4.9 5.6 6.1 8.4 · · ·
Quick Ratio 4-point trend, -42.4% 4.7 5.4 5.9 8.1 · · ·
Interest Coverage 2-point trend, +55.4% · · -9294.7 -20839.2 · · ·
Eficiencia 2
Datos anuales de Eficiencia para DNA
Métrica Tendencia 2025202420232022202120202019
Asset Turnover 4-point trend, -34.2% 0.1 0.1 0.1 0.2 · · ·
Receivables Turnover 4-point trend, +64.9% 7.4 11.6 5.1 4.5 · · ·
Por Acción 5
Datos anuales de Por Acción para DNA
Métrica Tendencia 2025202420232022202120202019
Book Value / Share 4-point trend, +852.1% $8.74 $13.17 $0.55 $0.92 · · ·
Revenue / Share 4-point trend, +978.8% $3.07 $4.38 $0.13 $0.28 · · ·
Cash Flow / Share 4-point trend, -1955.0% $-3.08 $-6.16 $-0.15 $-0.15 · · ·
Cash / Share 4-point trend, +313.0% $2.87 $10.33 $0.47 $0.70 · · ·
EPS (TTM) 5-point trend, -305.8% $-5.64 $-10.54 $-18.37 $-50.20 $-1.39 · ·
Tasas de Crecimiento 3
Datos anuales de Tasas de Crecimiento para DNA
Métrica Tendencia 2025202420232022202120202019
Revenue YoY 5-point trend, -108.1% -25.1% -9.7% -47.4% 52.2% 309.4% · ·
Revenue CAGR 3Y 3-point trend, -159.9% -29.1% -10.2% 48.6% · · · ·
Revenue CAGR 5Y 17.3% · · · · · ·
Valoración (TTM) 10
Datos anuales de Valoración (TTM) para DNA
Métrica Tendencia 2025202420232022202120202019
Revenue TTM 5-point trend, -45.8% $170M $227M $251M $478M $314M · ·
Net Income TTM 5-point trend, +82.9% $-313M $-547M $-893M $-2.10B $-1.83B · ·
Market Cap 4-point trend, -99.6% $484M $534M $135.29B $127.90B · · ·
P/E 5-point trend, +99.4% -1.5 -0.9 -3.7 -1.3 -239.1 · ·
P/S 4-point trend, -98.9% 2.8 2.4 538.0 267.7 · · ·
P/B 4-point trend, -98.7% 1.0 0.7 123.3 73.7 · · ·
P / Tangible Book 5-point trend, -99.7% 1.1 0.8 140.2 81.7 351.4 · ·
P / Cash Flow 4-point trend, +99.4% -2.8 -1.7 -457.8 -507.1 · · ·
P / FCF 4-point trend, +99.4% -2.7 -1.4 -402.3 -420.1 · · ·
Earnings Yield 5-point trend, -16059.5% -67.9% -107.3% -27.2% -74.3% -0.42% · ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

Estado de resultados
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $170M$227M$251M$478M$314M
Margen Operativo % -185.3%-246.5%-343.8%-462.4%
Beneficio neto $-313M$-547M$-893M$-2.10B$-1.83B
EPS Diluido $-5.64$-10.54$-18.37$-50.20$-1.39
Balance general
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ratio corriente 4.95.66.18.4
Ratio Rápido 4.75.45.98.1
Flujo de Efectivo
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flujo de caja libre $-179M$-382M$-336M$-304M

Últimas noticias Noticias recientes que mencionan a esta empresa

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

📊

Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.

Tu selección se guarda y te sigue en todos los tickers.